View Older Stories View More Recent Stories

Nov 9, 2020 07:05AM Ionis to present at upcoming virtual investor conferences
Nov 6, 2020 03:00AM Ionis and Akcea Recognize FCS Awareness Day With Global Community Efforts to Celebrate Unsung Heroes
Nov 4, 2020 07:00AM Ionis reports third quarter 2020 financial results and recent business achievements
Nov 4, 2020 06:17AM Ionis Pharmaceuticals (IONS) Reports Pfizer (PFE) to Begin Phase 2b Clinical Study of Vupanorsen (AKCEA-ANGPTL3-LRx)
Nov 3, 2020 06:00PM Ionis and Akcea announce that Pfizer has initiated a Phase 2b clinical study of vupanorsen (AKCEA-ANGPTL3-LRx)
Oct 30, 2020 07:00AM Ionis and Akcea win prestigious Prix Galien Award for TEGSEDI® (inotersen) as Best Biotechnology Product
Oct 22, 2020 07:05AM Ionis' third novel antisense medicine for ALS, its first designed to treat a broad ALS population, begins clinical trial
Oct 21, 2020 07:05AM Ionis to hold third quarter 2020 financial results webcast
Oct 15, 2020 07:11AM Ionis Pharmaceuticals (IONS) antisense medicine being evaluated in an investigator-initiated clinical study of COVID-19 patients in Brazil
Oct 15, 2020 07:05AM Ionis antisense medicine being evaluated in an investigator-initiated clinical study of COVID-19 patients in Brazil
Oct 13, 2020 07:05AM Ionis' inhaled antisense medicine demonstrates potential as a novel treatment for cystic fibrosis
Oct 13, 2020 07:05AM /C O R R E C T I O N -- Ionis Pharmaceuticals, Inc./
Oct 12, 2020 09:00AM Ionis Pharmaceuticals completes acquisition of Akcea Therapeutics
Oct 1, 2020 04:05PM Ionis Chief Scientific Officer Frank Bennett receives Lifetime Achievement Award from Oligonucleotide Therapeutics Society
Oct 1, 2020 06:20AM Ionis Pharmaceuticals (IONS), Genuity Science announce agreement designed to rapidly translate genomic insights into therapeutics
Oct 1, 2020 06:00AM Ionis and Genuity Science announce agreement designed to rapidly translate genomic insights into therapeutics
Sep 30, 2020 04:05PM Ionis Pharmaceuticals (IONS) treatment for Alexander disease receives orphan drug designation from U.S. FDA
Sep 30, 2020 04:05PM Ionis treatment for Alexander disease receives orphan drug designation from U.S. FDA
Sep 18, 2020 06:17AM Akcea Therapeutics (AKCA) Announces WAYLIVRA to Be Available on the NHS in England
Sep 18, 2020 03:00AM WAYLIVRA▼® (volanesorsen), the First and Only Therapy for FCS, an Ultra-Rare and Life-Threatening Condition, to Be Available on the NHS in England
Sep 3, 2020 07:05AM Ionis to present at upcoming virtual investor conferences
Sep 2, 2020 05:13PM Ionis Pharmaceuticals (IONS) announces NEJM publishes study results evaluating Ionis antisense therapy in treatment of patients with hereditary angioedema
Sep 2, 2020 05:10PM New England Journal of Medicine publishes study results evaluating Ionis antisense therapy in treatment of patients with hereditary angioedema
Aug 31, 2020 07:21AM Ionis Pharmaceuticals (IONS) to acquire remaining stake in Akcea Therapeutics (AKCA) for $18.15/sh
Aug 31, 2020 06:55AM Ionis Pharmaceuticals to acquire remaining stake in Akcea Therapeutics
Aug 31, 2020 06:01AM Akcea Therapeutics (AKCA), Ionis Pharmaceuticals, Inc. (IONS) Highlight Positive Phase 2 Clinical Data of Vupanorsen (AKCEA-ANGPTL3-L(Rx))
Aug 31, 2020 06:00AM Akcea Therapeutics (AKCA), Ionis Pharmaceuticals, Inc. (IONS) Present Positive Phase 2 Clinical Data of AKCEA-APOCIII-L(Rx)
Aug 29, 2020 04:00AM Positive Phase 2 Clinical Data of Vupanorsen (AKCEA-ANGPTL3-L(Rx)) Presented at ESC Congress 2020
Aug 29, 2020 03:30AM Positive Phase 2 Clinical Data of AKCEA-APOCIII-L(Rx) Presented at ESC Congress 2020
Aug 26, 2020 07:05AM Ionis Pharmaceuticals to hold cardio-renal franchise webcast
Aug 24, 2020 07:00AM Akcea and Ionis to Present Phase 2 Clinical Data of Vupanorsen (AKCEA-ANGPTL3-L (Rx) ) at ESC Congress 2020
Aug 18, 2020 07:07AM Akcea Therapeutics (AKCA), Ionis (IONS) to Present Phase 2 Results of AKCEA-APOCIII-L(Rx) in Late-Breaking Presentation at ESC Congress 2020
Aug 18, 2020 07:00AM Akcea and Ionis to Present Phase 2 Results of AKCEA-APOCIII-L(Rx) in Late-Breaking Presentation at ESC Congress 2020
Aug 13, 2020 07:00AM Akcea Announces New Pricing and Reimbursement of WAYLIVRA® (volanesorsen) in Germany
Aug 5, 2020 07:00AM Ionis reports second quarter 2020 financial results and recent business achievements
Aug 4, 2020 04:05PM Akcea Reports Financial Results and Highlights for Second Quarter 2020
Jul 22, 2020 07:13AM Akcea Therapeutics (AKCA) Announces Approval for Reimbursement of TEGSEDI in Austria for Treatment of Hereditary Transthyretin Amyloidosis with Polyneuropathy
Jul 22, 2020 07:05AM Ionis Pharmaceuticals to hold second quarter 2020 financial results webcast
Jul 22, 2020 07:00AM Akcea Announces Approval for Reimbursement of TEGSEDI® (inotersen) in Austria for Treatment of Hereditary Transthyretin Amyloidosis with Polyneuropathy
Jul 21, 2020 07:31AM Biogen (BIIB) Begins Phase 4 Study Evaluating Benefit of SPINRAZA (nusinersen) in Patients Treated with Zolgensma (onasemnogene abeparvovec)
Jul 21, 2020 07:30AM Biogen Plans to Initiate Phase 4 Study Evaluating Benefit of SPINRAZA® (nusinersen) in Patients Treated with Zolgensma® (onasemnogene abeparvovec)
Jul 21, 2020 07:00AM Akcea Therapeutics to Hold Second Quarter 2020 Financial Results Webcast
Jul 20, 2020 07:00AM Akcea Appoints New Senior Vice President, Global Medical Affairs
Jul 9, 2020 07:05AM Akcea Therapeutics (AKCA) Announces Appointment of New Chief Medical Officer
Jul 9, 2020 07:00AM Akcea Announces Appointment of New Chief Medical Officer
Jul 7, 2020 07:05AM Ionis Pharmaceuticals to hold neurology franchise webcast
Jun 29, 2020 07:00AM Akcea Appoints Tracy Palmer Berns as Chief Compliance Officer
Jun 17, 2020 07:00AM Akcea Therapeutics to Present at the BMO 2020 Prescriptions for Success Healthcare Conference
Jun 10, 2020 07:32AM Biogen (BIIB) Announces New Results From Landmark NURTURE Study Show That Pre-Symptomatic SMA Patients Treated With SPINRAZA Continue to Demonstrate Sustained Benefit From Treatment
Jun 10, 2020 07:30AM New Results From Landmark NURTURE Study Show That Pre-Symptomatic SMA Patients Treated With SPINRAZA® (nusinersen) Continue to Demonstrate Sustained Benefit From Treatment
View More Recent Stories View Older Stories